| Literature DB >> 24618023 |
Matthew Suderman, Nada Borghol, Jane J Pappas, Snehal M Pinto Pereira, Marcus Pembrey, Clyde Hertzman, Chris Power, Moshe Szyf1.
Abstract
BACKGROUND: Childhood abuse is associated with increased adult disease risk, suggesting that processes acting over the long-term, such as epigenetic regulation of gene activity, may be involved. DNA methylation is a critical mechanism in epigenetic regulation. We aimed to establish whether childhood abuse was associated with adult DNA methylation profiles.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24618023 PMCID: PMC4007631 DOI: 10.1186/1755-8794-7-13
Source DB: PubMed Journal: BMC Med Genomics ISSN: 1755-8794 Impact factor: 3.063
Figure 1Promoter methylation associated with childhood abuse. Heatmap showing MeDIP probe values from the 997 differentially methylated promoters (rows) across all 40 participants (columns). Each promoter is represented by the probe most associated with childhood abuse. Blackened squares above the columns denote non-abuse males, white squares denote those with childhood abuse. Other covariates included are childhood and adulthood socio-economic position (white = low, gray = high). Neither appears to explain the main sample clusters.
Characteristics of the 40 male study participants
| Birthweight, g, mean ± SD# | 0 | 3577.35 (574.91) | 3338.21 (590.25) | 0.24 |
| Height, cm, mean ± SD#$ | 7 | 1.24 (0.07) | 1.21 (0.07) | 0.27 |
| Maths score, mean ± SD#$ | 16 | 14.82 (7.32) | 12.29 (7.95) | 0.44 |
| Reading score, median (Q1, Q3)#$ | 16 | 27 (21, 31) | 31 (12, 32) | 0.70 |
| Socio-emotional adjustment number ~ median (Q1-Q3)#$ | 7 | 4 (1, 12) | 8.5 (2, 13) | 0.47 |
| Alcohol drinks daily, n (%)# | 42 | 7 (25.93) | 2 (16.67) | 0.53 |
| Smokers, n (%)# | 42 | 7 (25.93) | 4 (33.33) | 0.64 |
| Height, cm, mean ± SD# | 42 | 1.78 (0.09) | 1.76 (0.06) | 0.52 |
| BMI, kg/m2, mean ± SD | 45 | 26.63 (3.99) | 28.69 (4.39) | 0.16 |
| Waist circumference, cm, mean ± SD | 45 | 97.43 (10.24) | 102 (12.02) | 0.23 |
| Diastolic blood pressure, mmHg, mean ± SD | 45 | 82.77 (11.71) | 85.53 (12.72) | 0.51 |
| Systolic blood pressure, mmHg, mean ± SD | 45 | 132.92 (18.61) | 134.72 (18.90) | 0.78 |
| Fev1†, mean ± SD# | 45 | 3.84 (0.65) | 3.70 (0.63) | 0.53 |
†FEV1 = one-second forced expiratory volume; best test of three spirometry readings.
#N for non-abuse <28 (range 22 to 27).
$N for abuse <12 (range 7 to 10).
~higher score = poorer adjustment.
*p-value from t-test, except for median (IQR), when Two-sample Wilcoxon rank-sum test was used.
Figure 2Validation of MeDIP results. A. Quantification of methylation differences in the abuse and non-abuse groups by bisulfite pyrosequencing analysis of the SLC17A3 promoter and the PM20D1 first exon and intron. DNA methylation at 14 CpG sites in the SLC17A3 promoter and 12 and 1 CpG sites in the PM20D1 first exon and first intron, respectively, among the abuse and non-abuse groups is shown (N = 10 vs. 26 for SLC17A3; N = 9 vs 23 for PM20D1). One-sided t-tests were applied to each CpG site to test for association of methylation levels with childhood abuse, and false discovery rates were calculated for the resulting p-values in order to correct for multiple testing. All false discovery rates (FDR) were less than 0.1, indicating significant association between CpG methylation levels and childhood abuse. **: FDR < 0.025; *: FDR < 0.05; ++: FDR < 0.1; +: FDR < 0.2. The bars represent average methylation for all subjects in a group and error bars indicate the standard error of the mean. Physical maps of the regions analyzed are presented above the charts where CpG positions are indicated by balloons. The transcription start site (TSS) is indicated by a hook arrow. The positions of the primers used for pyrosequencing (Additional file 3: Table S2) are indicated by arrows. B. Replication of the quantification of the differences in methylation at PM20D1 between the abuse and non-abuse groups in an additional 27 males that were not profiled using MeDIP (N = 7 vs. 20). Pyrosequencing was applied to measure the methylation levels of 13 CpG sites in the first exon and intron of PM20D1.
Selected functional analysis of abuse associated hypo- and hypermethylation
| WNT signaling pathway | 142 | 19 | 0.0013 | 15 | 0.0020 | 0.53 | 4 | 0.22 | 1 |
| Regulation | 2330 | 169 | 0.017 | 134 | 0.0018 | 0.51 | 33 | 0.88 | 1 |
| - Chromatin modification | 273 | 32 | 0.0004 | 28 | 0.00005 | 0.09 | 4 | 0.68 | 1 |
| - Histone modification | 105 | 13 | 0.013 | 11 | 0.008 | 0.94 | 2 | 0.53 | 1 |
| - Transcription factor binding | 493 | 41 | 0.034 | 35 | 0.006 | 0.84 | 6 | 0.84 | 1 |
| Development | 3054 | 230 | 0.0007 | 172 | 0.00096 | 0.40 | 58 | 0.17 | 1 |
| - Multicellular organismal development | 2838 | 213 | 0.0012 | 163 | 0.0006 | 0.32 | 50 | 0.32 | 1 |
| Cell surface receptor linked signal transduction | 1778 | 125 | 0.071 | 79 | 0.60 | 1 | 46 | 0.002 | 0.53 |
‘n’ is the number of genes in the relevant pathway that are differentially methylated in association with abuse.
‘p’ was calculated using the hypergeometric test, it indicates the statistical significance of the enrichment.
‘fdr’ the false discovery rate (FDR) corresponding to the p-value.
Figure 3Differential methylation in the signaling pathway. The KEGG (http://www.genome.jp/kegg/mapper.html) depiction of the WNT signaling pathway is shown with hypermethylated gene promoters (more methylated in the group with childhood abuse) colored red and the hypomethylated gene promoters colored blue.
Methylation of microRNAs and their target genes
| mir-514 | 49 | 10 | 1 | AFF4, BAALC, BRWD1, CARM1, ENAH, KLF13, MYO1B, NR3C1, SVIL, TCF12 | 5.71E-05 | |
| let-7d | 320 | 26 | 6 | ATP2A2, BACH1, BRWD1, CDV3, CHD4, CPSF4, DCUN1D2, DOCK3, DOT1L, EFHD2, EZH2, GGA3, LIMD2, LRIG1, MECP2, MGAT4A, MIB1, MLL5, PARD6B, PBX3, PRTG, PTPRU, RDH10, SOCS1, UNC5A, WDR37 | 0.0030 | |
| mir-520c | 274 | 23 | 3 | ASF1B, BCL2L11, BRP44L, DDHD1, DPYSL5, FLT1, FNDC3B, INHBB, KCNMA1, KLF13, MAP3K14, MECP2, MKNK2, MTUS1, ORMDL3, PBX3, PFN2, RGL1, SMAD2, UBE2Q2, WDR37, ZFP36L2, ZFPM2 | 0.0035 | |
| mir-215 | 37 | 6 | 0 | ARFGEF1, FNDC3B, GRHL1, KLHDC5, LRRFIP1, MECP2 | 0.0060 | |
| mir-519a | 377 | 28 | 4 | AFF4, BRWD1, BTG3, CELSR2, DNAJB6, LRIG1, MAP3K5, MAP4, MASTL, MCM7, MECP2, MIB1, NPAS2, OBFC2A, PARD6B, PFN2, PTHLH, RAPGEF4, RASD1, SCAMP2, SFRS2, SMOC2, TMEM64, VGLL3, WHSC1, YES1, ZFPM2, ZFYVE9 | 0.0074 | |
| mir-519e | 104 | 11 | 2 | ARHGEF12, ARL4C, BCOR, CCNG2, CTDSPL2, DLL1, DPYSL5, EFNB3, NEDD4L, NPAS2, RAB35 | 0.0075 | |
| mir-203 | 239 | 20 | 3 | AFF4, BCL7A, CNTFR, CTDSPL2, DNMT3B, EGR1, FALZ, INSIG1, KCTD9, LASP1, MECP2, PLD2, PPM1B, RAPGEF4, SLC12A2, SMAD1, SPEN, SPIRE1, TCF12, YWHAQ | 0.0064 |
MicroRNAs are listed that have statistically significant MeDIP differences between abuse and non-abuse groups whose predicted gene targets are enriched for gene promoters that are also differentially methylated between abuse and non-abuse groups. In each case, enrichment is for targets with lower methylation in the abused group.
“enrichment p-value” indicates the level of enrichment for hypomethylated targets.
“microRNA methylation” indicates whether the data predicts significantly higher (“hypermethylated”) or lower (“hypomethylated”) methylation levels in the abuse group.
Figure 4Megabase regions enriched with methylation differences. Promoter MeDIP differences across chromosomes 16 (A), 17 (B) and X (C) and across two smaller genomic regions (D) and (E) are shown using images obtained from the UCSC Genome Browser. The top track depicts average differences of log abuse – log non-abuse. Each bar in the middle track identifies a significant difference. Bars above or below the horizontal line identify sites with higher or lower methylation in the abused group. The bottom track indicates relative gene abundance across the chromosome.